vs
Side-by-side financial comparison of JFrog Ltd (FROG) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
JFrog Ltd is the larger business by last-quarter revenue ($145.3M vs $86.8M, roughly 1.7× IOVANCE BIOTHERAPEUTICS, INC.). On growth, JFrog Ltd posted the faster year-over-year revenue change (25.2% vs 17.7%). JFrog Ltd produced more free cash flow last quarter ($49.9M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 20.4%).
JFrog Ltd is a global DevOps technology provider that delivers end-to-end software release, artifact management, and security solutions. It serves clients across tech, finance, retail, and manufacturing sectors, helping teams streamline development and delivery workflows for cloud, on-premises, and hybrid infrastructure.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
FROG vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $145.3M | $86.8M |
| Net Profit | $-15.2M | — |
| Gross Margin | 77.9% | 67.4% |
| Operating Margin | -14.7% | -84.7% |
| Net Margin | -10.5% | — |
| Revenue YoY | 25.2% | 17.7% |
| Net Profit YoY | 34.4% | — |
| EPS (diluted) | $-0.13 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $145.3M | $86.8M | ||
| Q3 25 | $136.9M | $67.5M | ||
| Q2 25 | $127.2M | $60.0M | ||
| Q1 25 | $122.4M | $49.3M | ||
| Q4 24 | $116.1M | $73.7M | ||
| Q3 24 | $109.1M | $58.6M | ||
| Q2 24 | $103.0M | $31.1M | ||
| Q1 24 | $100.3M | $715.0K |
| Q4 25 | $-15.2M | — | ||
| Q3 25 | $-16.4M | $-91.3M | ||
| Q2 25 | $-21.7M | $-111.7M | ||
| Q1 25 | $-18.5M | $-116.2M | ||
| Q4 24 | $-23.2M | — | ||
| Q3 24 | $-22.9M | $-83.5M | ||
| Q2 24 | $-14.3M | $-97.1M | ||
| Q1 24 | $-8.8M | $-113.0M |
| Q4 25 | 77.9% | 67.4% | ||
| Q3 25 | 77.4% | 43.0% | ||
| Q2 25 | 76.3% | 5.5% | ||
| Q1 25 | 75.3% | -0.8% | ||
| Q4 24 | 75.4% | 68.7% | ||
| Q3 24 | 75.0% | 46.2% | ||
| Q2 24 | 78.8% | -0.8% | ||
| Q1 24 | 79.5% | — |
| Q4 25 | -14.7% | -84.7% | ||
| Q3 25 | -15.8% | -140.7% | ||
| Q2 25 | -20.4% | -189.8% | ||
| Q1 25 | -18.8% | -245.8% | ||
| Q4 24 | -21.9% | -117.5% | ||
| Q3 24 | -27.4% | -152.1% | ||
| Q2 24 | -18.6% | -327.6% | ||
| Q1 24 | -16.6% | -16464.6% |
| Q4 25 | -10.5% | — | ||
| Q3 25 | -12.0% | -135.3% | ||
| Q2 25 | -17.0% | -186.2% | ||
| Q1 25 | -15.1% | -235.5% | ||
| Q4 24 | -20.0% | — | ||
| Q3 24 | -21.0% | -142.7% | ||
| Q2 24 | -13.9% | -312.2% | ||
| Q1 24 | -8.8% | -15800.8% |
| Q4 25 | $-0.13 | — | ||
| Q3 25 | $-0.14 | — | ||
| Q2 25 | $-0.19 | $-0.33 | ||
| Q1 25 | $-0.16 | $-0.36 | ||
| Q4 24 | $-0.21 | $-0.24 | ||
| Q3 24 | $-0.21 | $-0.28 | ||
| Q2 24 | $-0.13 | $-0.34 | ||
| Q1 24 | $-0.08 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $704.4M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $887.4M | $698.6M |
| Total Assets | $1.3B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $704.4M | $297.0M | ||
| Q3 25 | $651.1M | $300.8M | ||
| Q2 25 | $611.7M | $301.2M | ||
| Q1 25 | $563.5M | $359.7M | ||
| Q4 24 | $522.0M | $323.8M | ||
| Q3 24 | $467.8M | $397.5M | ||
| Q2 24 | $591.3M | $412.5M | ||
| Q1 24 | $579.6M | $356.2M |
| Q4 25 | $887.4M | $698.6M | ||
| Q3 25 | $859.4M | $702.3M | ||
| Q2 25 | $826.5M | $698.5M | ||
| Q1 25 | $800.0M | $767.9M | ||
| Q4 24 | $773.5M | $710.4M | ||
| Q3 24 | $756.2M | $773.5M | ||
| Q2 24 | $721.4M | $768.5M | ||
| Q1 24 | $707.8M | $680.0M |
| Q4 25 | $1.3B | $913.2M | ||
| Q3 25 | $1.3B | $904.9M | ||
| Q2 25 | $1.2B | $907.4M | ||
| Q1 25 | $1.2B | $966.7M | ||
| Q4 24 | $1.1B | $910.4M | ||
| Q3 24 | $1.1B | $991.1M | ||
| Q2 24 | $1.0B | $964.3M | ||
| Q1 24 | $997.1M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $50.7M | $-52.6M |
| Free Cash FlowOCF − Capex | $49.9M | $-61.9M |
| FCF MarginFCF / Revenue | 34.3% | -71.3% |
| Capex IntensityCapex / Revenue | 0.6% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $142.3M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $50.7M | $-52.6M | ||
| Q3 25 | $30.2M | $-78.7M | ||
| Q2 25 | $36.1M | $-67.4M | ||
| Q1 25 | $28.8M | $-103.7M | ||
| Q4 24 | $49.1M | $-73.3M | ||
| Q3 24 | $27.6M | $-59.0M | ||
| Q2 24 | $16.7M | $-98.4M | ||
| Q1 24 | $17.5M | $-122.3M |
| Q4 25 | $49.9M | $-61.9M | ||
| Q3 25 | $28.8M | $-89.5M | ||
| Q2 25 | $35.5M | $-74.9M | ||
| Q1 25 | $28.1M | $-109.9M | ||
| Q4 24 | $48.5M | $-77.5M | ||
| Q3 24 | $26.7M | $-61.3M | ||
| Q2 24 | $16.0M | $-98.9M | ||
| Q1 24 | $16.6M | $-126.5M |
| Q4 25 | 34.3% | -71.3% | ||
| Q3 25 | 21.0% | -132.7% | ||
| Q2 25 | 27.9% | -124.9% | ||
| Q1 25 | 23.0% | -222.8% | ||
| Q4 24 | 41.8% | -105.1% | ||
| Q3 24 | 24.5% | -104.6% | ||
| Q2 24 | 15.5% | -317.9% | ||
| Q1 24 | 16.6% | -17685.3% |
| Q4 25 | 0.6% | 10.7% | ||
| Q3 25 | 1.0% | 16.1% | ||
| Q2 25 | 0.5% | 12.4% | ||
| Q1 25 | 0.5% | 12.6% | ||
| Q4 24 | 0.5% | 5.7% | ||
| Q3 24 | 0.9% | 3.9% | ||
| Q2 24 | 0.7% | 1.4% | ||
| Q1 24 | 0.8% | 583.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FROG
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
